The EMBO Journal11d
Type-2 innate signals are dispensable for skeletal muscle regeneration and pathology linked to Duchenne muscular dystrophy
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
Genetic mechanisms underlying Duchenne muscular dystrophy point to potential treatments
Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...
Baylor College of Medicine17d
Muscular Dystrophy
The rate of progression of the muscular dystrophies depends on the type of dystrophy. While some progress slowly, others confine the patient to a wheelchair within a few years. Significant advances in ...
BioWorld8d
Repurposing CFTR corrector to treat muscular dystrophies caused by misfolded α-sarcoglycan
Limb-girdle muscular dystrophy type 2D (LGMD2D/R3) is a rare genetic disorder caused by mutations in the SGCA gene, leading to defective folding and the loss of functional α-sarcoglycan, with ...
pharmaphorum2d
Sanofi wagers $400m on miRecule muscular dystrophy therapy
FSHD is the second most common form of muscular dystrophy after the Duchenne type, and affects around 1 ... which included a $2 million grant from the National Cancer Institute in the US.
Morningstar10d
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
The company's portfolio of FDA-approved brands includes: In addition to this Duchenne muscular dystrophy program, the company also has Phase 2 clinical studies underway evaluating its ifetroban ...
Nasdaq11d
Entrada Therapeutics Authorizes Phase 1/2 Clinical Trial for ENTR-601-44 to Treat Duchenne Muscular Dystrophy, On Track for Q2 2025 Initiation
a Phase 1/2 clinical study of ENTR-601-44 targeting Duchenne muscular dystrophy (DMD). This study will evaluate the safety, tolerability, and effectiveness of ENTR-601-44 in patients with specific ...